I am mostly a buyer of high quality dividend stocks, with solid competitive advantages. My holding period is forever, as long as the dividend is at least maintained. I tend to concentrate my efforts on stocks which grow earnings and dividends, which
Michael Bigger is an investor and a trader who has been involved with trading technologies for more than twenty years. He runs the Bigger Capital Fund, LP and he manages money for many institutional investors.
Risk and portfolio manager. Former long/short hedge fund manager and prop trader. 20 years of market experience. Started career on Wall Street in the heady 1990s. MBA in Finance from NYU Stern. @seeitmarket contributor. Opinions are my own.
Penn State Econ major~Scholar of Behavioral Finance & 30yr mkt trader~Proponent of the notion that psychology & emotion recurrently contest the efficient market hypothesis*DISCLAIMER:NEVER trade any security based on my opinions~Live Life~Smile Often
Welcome to StockTwits, home of the human ticker, real time pulse of markets, and sentiment machine. Use StockTwits to follow your favorite stock, investor or trader and dive deep into open analysis and debate.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease.